Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...
Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose ...
AiRO's fitter network now spans 30 top-tier experts and studios trusted by riders of every level. These fitters have embraced AiRO to deliver high-performance, data-driven fits that were previously ...
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle ® molecules, for diseases that are underserved by existing therapeutics.
Irvine, CA - 12/1/2025 - The National Bicycle Dealers Association (NBDA) today announced the launch of its groundbreaking Market Intelligence Program, providing Specialty Bicycle Retailers with ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...
Today’s technological advancements are taking us to new heights and providing us with chances that were unthinkable only a few decades ago. Perhaps the biggest contributor to human advancement is the ...
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback